Vitamin E therapy for NAFLD/NASH

Nutrition

Volumn 31, Issue 6, 2015, Pages 898-899

  Yoneda, Masashi ^a   Hasegawa, Takenao ^b   Sato, Ken ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b Oketo Red Cross Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINOTRANSFERASE; PIOGLITAZONE; PLACEBO; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE;

AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HUMAN; LETTER; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; DIET SUPPLEMENTATION; HEPATITIS C, CHRONIC; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ALANINE TRANSAMINASE; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; DIETARY SUPPLEMENTS; HEPATITIS C, CHRONIC; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; VITAMIN E;

EID: 84928531498     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.08.007     Document Type: Letter

References (11)

1. Ji H.F., Sun Y., Shen L. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: Results from a meta-analysis. Nutrition 2014, 30:986-991.
2. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 y. Hepatology 1990, 11:74-80.
3. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
4. Day C.P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002, 16:663-678.
5. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
6. Levene A.P., Goldin R.D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012, 61:141-152.
7. Poli G., Albano E., Biasi F., Cecchini G., Carini R., Belloma G., et al. Lipid peroxidation stimulated by carbon tetrachloride or iron and hepatocyte death: Protective effect of vitamin E. Free radicals in liver injury 1985, 207-215. IRL Press Ltd., Oxford. G. Poli, K.H. Cheeseman, M.U. Diazani, T.F. Slater (Eds.).
8. Parola M., Muraca R., Dianzani I., Barrera G., Leonarduzzi G., Bendinelli P., et al. Vitamin E dietary supplementation inhibits transforming growth factor β1 gene expression in the rat liver. FEBS Lett 1992, 308:267-270.
9. Hasegawa T., Yoneda M., Nakamura K., Makino I., Terano A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ter 2001, 15:1667-1672.
10. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
11. Lavine J.E., Schwimmer J.B., Van Natta M.L., Molleston J.P., Murray K.F., Rosenthal P., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. JAMA 2011, 305:1659-1668.